Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davis Y Torrejon

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cancer Immunology Research|October 6, 2023
Antitumor Immune Responses in B2M-Deficient CancersDavis Y Torrejon, Mildred Galvez, Gabriel Abril-Rodriguez, et al.
Cancer Research Communications|January 2, 2023
Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockadeGabriel Abril-Rodríguez, Davis Y Torrejon, Daniel Karin, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1Sharareh Gholamin, Heini M Natri, Yuqi Zhao, et al.
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Cancer Cell|September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cancer Immunology Research|October 6, 2023
Antitumor Immune Responses in B2M-Deficient CancersDavis Y Torrejon, Mildred Galvez, Gabriel Abril-Rodriguez, et al.
Cancer Research Communications|January 2, 2023
Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockadeGabriel Abril-Rodríguez, Davis Y Torrejon, Daniel Karin, et al.
The Journal of Clinical Investigation|April 29, 2021
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti-PD-1 therapyYeon Joo Kim, Katherine M Sheu, Jennifer Tsoi, et al.
Cell Reports|May 13, 2017
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 ExpressionAngel Garcia-Diaz, Daniel Sanghoon Shin, Blanca Homet Moreno, et al.
Biorxiv : the Preprint Server for Biology|April 16, 2025
Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1Sharareh Gholamin, Heini M Natri, Yuqi Zhao, et al.
Nature Cancer|August 9, 2021
PAK4 inhibition improves PD-1 blockade immunotherapyGabriel Abril-Rodriguez, Davis Y Torrejon, Wei Liu, et al.
Cancer Discovery|May 30, 2020
Overcoming Genetically Based Resistance Mechanisms to PD-1 BlockadeDavis Y Torrejon, Gabriel Abril-Rodriguez, Ameya S Champhekar, et al.
Cancer Discovery|December 2, 2016
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 MutationsDaniel Sanghoon Shin, Jesse M Zaretsky, Helena Escuin-Ordinas, et al.
The New England Journal of Medicine|July 20, 2016
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M Zaretsky, Angel Garcia-Diaz, Daniel S Shin, et al.
Cancer Cell|September 11, 2020
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in MelanomaCatherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, et al.
Pageof 1